EPITHELIOID SARCOMA
Clinical trials for EPITHELIOID SARCOMA explained in plain language.
Never miss a new study
Get alerted when new EPITHELIOID SARCOMA trials appear
Sign up with your email to follow new studies for EPITHELIOID SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like certain brain, kidney, and soft tissue tumors) have returned or not responded to treatment. These cancers lack specific genes (SMARCB1 or SMARCA4), making them …
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
New drug combo shows promise against rare sarcomas
Disease control OngoingThis study tests whether combining T-VEC (a virus that attacks cancer cells) with pembrolizumab (an immunotherapy) can shrink tumors in people with advanced sarcoma that cannot be removed by surgery. About 41 adults with certain sarcoma types will receive both drugs. The main goa…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:03 UTC
-
New drug cocktail targets rare childhood cancers
Disease control OngoingThis study tests a combination of three drugs (tazemetostat, nivolumab, and ipilimumab) for children with rare tumors that lack certain proteins (INI1 or SMARCA4). The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific cancers like…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Susan Chi, MD • Aim: Disease control
Last updated May 26, 2026 05:01 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat childhood tumors
Disease control OngoingThis study is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink or control rare INI1-negative cancers in children and young adults. These cancers have come back or not responded to standard treatments. The goal is to see if the drugs help the…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:59 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control OngoingThis study tests whether adding the drug pazopanib to standard radiation or chemoradiation helps shrink soft tissue sarcomas before surgery. About 140 patients with newly diagnosed, removable tumors took part. The goal is to see if the combination is safe and improves tumor respo…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC